Credit Industriel ET Commercial Grows Position in Alumis Inc. $ALMS

Credit Industriel ET Commercial boosted its position in shares of Alumis Inc. (NASDAQ:ALMS) by 178.8% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 387,002 shares of the company’s stock after buying an additional 248,202 shares during the quarter. Credit Industriel ET Commercial’s holdings in Alumis were worth $1,161,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Bank of New York Mellon Corp grew its position in shares of Alumis by 37.0% in the 1st quarter. Bank of New York Mellon Corp now owns 42,403 shares of the company’s stock worth $260,000 after buying an additional 11,453 shares during the period. Towerview LLC boosted its stake in Alumis by 3.6% during the first quarter. Towerview LLC now owns 430,000 shares of the company’s stock worth $2,640,000 after acquiring an additional 15,000 shares in the last quarter. BML Capital Management LLC purchased a new stake in Alumis in the first quarter worth about $305,000. Charles Schwab Investment Management Inc. increased its stake in shares of Alumis by 12.7% during the first quarter. Charles Schwab Investment Management Inc. now owns 127,854 shares of the company’s stock valued at $785,000 after purchasing an additional 14,453 shares in the last quarter. Finally, Invesco Ltd. bought a new position in shares of Alumis during the first quarter valued at approximately $164,000.

Alumis Price Performance

NASDAQ ALMS opened at $4.72 on Friday. The company has a 50-day moving average price of $4.43 and a 200-day moving average price of $4.16. Alumis Inc. has a 52 week low of $2.76 and a 52 week high of $12.29. The firm has a market capitalization of $491.16 million, a P/E ratio of -1.00 and a beta of -1.33.

Alumis (NASDAQ:ALMS) last released its earnings results on Wednesday, August 13th. The company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.06). The company had revenue of $2.67 million during the quarter, compared to the consensus estimate of $1.80 million. As a group, equities research analysts anticipate that Alumis Inc. will post -8.51 EPS for the current year.

Wall Street Analyst Weigh In

ALMS has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of Alumis in a research note on Thursday, August 14th. Wells Fargo & Company initiated coverage on Alumis in a research note on Friday, July 25th. They issued an “overweight” rating and a $17.00 target price on the stock. Wall Street Zen upgraded Alumis from a “strong sell” rating to a “hold” rating in a report on Saturday, August 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alumis in a research note on Wednesday, October 8th. Finally, Morgan Stanley cut their price objective on shares of Alumis from $23.00 to $22.00 and set an “overweight” rating on the stock in a research report on Friday, August 15th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $19.20.

Alumis Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.